George Kemble

SAT-437 Denifanstat improves multiple qFibrosis-based collagen features linked to major adverse liver outcomes in patients with metabolic dysfunction-associated steatohepatitis patients and high polygenic risk

Mary E. Rinella, Philip N. Newsome, Vlad Ratziu, Brent A. Neuschwander‐Tetri et autres

WED-480 Denifanstat-mediated reduction of plasma glycine- and taurineconjugated bile acids correlates with histological improvements in denifanstat-treated metabolic dysfunction-associated steatohepatitis patients in phase 2b FASCINATE-2 study

Rohit Loomba, Wen-Wei Tsai, Cristina Alonso, Alejandro Montilla et autres

THU-336 Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist resmetirom shows synergistic improvement of NAFLD activity score (NAS) within 6-weeks in diet-induced obese mice with biopsy-confirmed MASH

Wen-Wei Tsai, Malte Hasle Nielsen, Michael Feigh, Eduardo B. Martins et autres

THU-231 Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist, resmetirom, improved markers of NASH and cardiovascular health in LDL receptor knockout NASH mice

Wen-Wei Tsai, Eveline Gart, Martine C. Morrison, Geurt Stokman et autres

Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy

Ali Talebi, Vincent de Laat, Xander Spotbeen, Jonas Dehairs et autres

be, de, us (code pays fourni par la source)

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

Marie O’Farrell, G M Duke, R. Webster Crowley, Douglas Buckley et autres

us (code pays fourni par la source)

Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer

Caterina Bartolacci, Cristina Andreani, Gonçalo Vale, Stefano Berto et autres

us, it (code pays fourni par la source)

Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells

Barbara Schroeder, Travis Vander Steen, Ingrid Espinoza, Chandra M. K. Venkatapoorna et autres

us, de, es (code pays fourni par la source)

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial

Rohit Loomba, Rizwana Mohseni, Kathryn Jean Lucas, Julio Gutiérrez et autres

us, hk, fr (code pays fourni par la source)

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau, Manish R. Patel et autres

us, gb (code pays fourni par la source)

Fatty Acid Synthase Inhibitor TVB‐2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities

Majid Mufaqam Syed‐Abdul, Elizabeth J. Parks, Ayman H. Gaballah, Kimberlee Bingham et autres

us (code pays fourni par la source)

Abstract 708: Targeting fatty acid synthase induces apoptosis and senescence

Travis Van der Steen, George Kemble, Ruth Lupu

us (code pays fourni par la source)